
Washington – Health advisors begin meeting Thursday to review more than a half-dozen peptides, unproven substances that have become a growing trend in the wellness space despite little evidence that they are safe or effective.
The two-day meeting hosted by the Food and Drug Administration (FDA) is supported by Health Secretary Robert F. Kennedy Jr., who has described himself as a “big fan” of peptides and has pledged to reverse restrictions imposed on the sector under President Joe Biden.
Peptide advocates include podcaster Joe Rogan and wellness influencers like Gary Brecka, a supporter of Kennedy’s “Make America Healthy Again” initiative, who sells vials of peptides online. Social media is full of testimonials from people who claim that these substances have helped them build muscle mass, recover from injuries, or look younger.
Despite that support, the two-day FDA meeting is expected to reveal a sharp division of opinion on these compounds.
FDA scientists have made clear that they do not believe there is sufficient data to justify greater availability of peptides, specifically through compounding pharmacies, which prepare custom medications not marketed by traditional pharmaceutical manufacturers.
That is also the position of many medical and scientific experts who have expressed their opinion before the meeting.
“This is really alarming,” said Rita Jew, a pharmacist and president of the Institute for Safe Medication Use. “There aren’t many other substances that people inject that have such a clear lack of clinical evidence.”
However, the group of outside advisors convened for the meeting includes at least seven doctors or pharmacists with financial ties to the peptide industry. The group has wellness clinic owners who sell peptides, pharmacies that make the formulas, and online counseling companies that promote them. Other think tanks appointed under Kennedy have come under fire for apparent conflicts of interest.
Earlier this week, the FDA added several more experts to the 20-member committee, including academics with no ties to industry.
FDA scientists remain unconvinced of safety, health benefits of peptides
Experts will vote on whether the FDA should allow seven commonly used peptides to be included on the list of safe substances for pharmaceutical preparations. The votes are not binding and the FDA has sometimes distanced itself from the recommendations of its outside experts.
Peptides are the basic components of more complex proteins and activate the hormones necessary for growth, metabolism and healing in the body. Several of them have been marketed as medications by pharmaceutical companies, including leading treatments for diabetes and weight loss.
Peptide advocates have asked the FDA to evaluate seven peptides being tested this week for the treatment of various medical conditions, including ulcerative colitis, migraines and opioid addiction.
In recent years, the FDA had warned Americans about the risks of injecting peptides such as BPC-157 and TB-500, which are scheduled for review this Thursday. These substances are promoted on the Internet as a way to recover from injuries and reduce inflammation. Both are considered doping substances by international sports authorities.
In a scientific review published before the meeting, FDA scientists reiterated their long-standing concerns. Time and again, regulators noted that they had found little data on safety or effectiveness and expressed concerns about contamination risks, allergic reactions and quality control. Most of the data they found came from studies in animals, including rats, and not in humans.
In the case of the seven peptides analyzed, the staff recommended that their use not be allowed for the preparation of compounding formulas.
Peptide advocates will pressure FDA to make access easier
The FDA evaluation is just one part of more than 18 hours of discussions and presentations scheduled over two days. The meeting also offers citizens the opportunity to address the FDA and its experts.
Before the meeting, the FDA received more than 1,900 public comments, including those from doctors and patients attesting to the benefits of peptides.
“For many people, it’s about a therapy that’s helping them, and whether they can get it safely and legally at a regulated pharmacy instead of taking their chances on the gray market,” says the American Academy of Peptide Medicine, a group of doctors and wellness clinic leaders who promote peptides. The group’s website notes that it is “an educational academy, not a licensing or accreditation body.”
After the meeting, the FDA will analyze the votes, debate and public comments before making a decision on whether to relax access to the peptides.
FDA experts say the most likely outcome could be a temporary measure that ensures pharmacies will not be subject to enforcement action for preparing the peptides under review. To officially include these substances on the FDA’s list of drugs suitable for compounding, new regulations would be needed, which can take months or years to develop.
“We are still in the middle of this process, but I think it is more than likely that the process will end up having the result that Secretary Kennedy wants,” said Nathan Beaver, an attorney who specializes in FDA matters.
This story was translated from English to Spanish with an artificial intelligence tool and was reviewed by an editor before publication.
